Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
uFraction8 is a private Scottish biotech engineering company developing microfluidics-based bioseparation systems for biomanufacturing. Its platform is designed to harvest, separate, concentrate, and dewater cells and biomass with high yield while preserving cell viability, offering an energy-efficient alternative to centrifugation and conventional filtration. The company targets applications across biopharma, microalgae, and alternative protein, including mammalian cell processing, viral vector and monoclonal antibody manufacturing, and continuous perfusion workflows. uFraction8 commercializes reusable, scalable filtration modules built from stacked microfluidic chips and has operations in Scotland and Poland. The company was founded in 2017 and has raised seed and grant financing to support technology development and commercialization in Europe and North America.
Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on uFraction8.